Vibe Growth Corporation (VIBEF) Fair Value & Analysis

Healthcare · US · Market cap $405K

A solid business, currently priced close to our fair value.

What matters now

• The model range is unusually wide ($0.2475 to $0.6901). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• The price sits close to our fair value, market and models broadly agree here, little valuation tension.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range $0.0013 – $89.00 · fair‑value band $0.2475 – $0.6901 · the $0.3900 price screens below the $0.4273 fair value. Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Vibe Growth Corporation (VIBEF) currently trades at $0.3900, while our model-based Fair Value estimate is $0.4273, implying the stock looks roughly 9.6% fairly valued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Vibe Growth Corporation generated revenue of $18.2M at a net margin of -15.1%. Revenue grew 26.2% year over year. Net debt stands at $1.7M. Fundamentals as of Jul 22, 2026

Our scenario range runs from $0.2475 (bear case) to $0.6901 (bull case); at $0.3900, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 67% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 10%, VIBEF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples ($7.23) versus Growth DCF ($0.1100). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Vibe Growth Corporation evaluates, acquires, and develops cannabis assets and retail cannabis dispensaries in the United States. The company operates a retail and e-commerce platform under the Vibe By California brand. Its biological assets consist of cannabis plants used for medical and recreational purposes.

Full company description

Vibe Growth Corporation evaluates, acquires, and develops cannabis assets and retail cannabis dispensaries in the United States. The company operates a retail and e-commerce platform under the Vibe By California brand. Its biological assets consist of cannabis plants used for medical and recreational purposes. The company also offers flower, edibles, pre rolls, vaporizers, topicals, and tinctures products. In addition, it operates retail dispensaries; cannabis greenhouse cultivation; indoor cultivation; commercial distribution and transportation; and e-commerce and home delivery. The company was formerly known as Vibe Bioscience Ltd. and changed its name to Vibe Growth Corporation in October 2020. Vibe Growth Corporation is headquartered in Sacramento, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Vibe Growth Corporation reported revenue of $17.5M in FY2025 versus $29.3M in FY2021, a compound −12.0%/yr. Reported net income was −$2.5M in FY2025.

Watch VIBEF: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 623 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.